Pierredon Sandra, Ribaux Pascale, Tille Jean-Christophe, Petignat Patrick, Cohen Marie
Department of Gynecology and Obstetrics, Faculty of Medicine, Geneva University Hospital, 1211 Geneva 14, Switzerland.
Department of Pathology, Geneva University Hospital, 1211 Geneva 14, Switzerland.
Oncol Lett. 2017 Jun;13(6):4965-4973. doi: 10.3892/ol.2017.6096. Epub 2017 Apr 25.
Ovarian cancer is one of the most common types of reproductive cancer, and has the highest mortality rate amongst gynecological cancer subtypes. The majority of ovarian cancers are diagnosed at an advanced stage, resulting in a five-year survival rate of ~30%. Early diagnosis of ovarian cancer has improved the five-year survival rate to ≥90%, thus the current imperative requirement is to identify biomarkers that would allow the early detection, diagnosis and monitoring of the progression of the disease, or of novel targets for therapy. In the present study, secreted proteins from purified ovarian control, benign and cancer cells were investigated by mass spectrometry, in order to identify novel specific markers that are easy to quantify in patients sera. A total of nine proteins revealed significant differential secretion from control and benign cells, in comparison with ovarian cancer cells. The mRNA expression levels of three of these proteins (Dickkopf protein 3, heat shock protein 10 kDa and gelsolin) were subsequently evaluated by reverse transcription-quantitative polymerase chain reaction. Combined with the protein level in serum, the present study identified that gelsolin may be a useful marker of ovarian cancer.
卵巢癌是最常见的生殖系统癌症类型之一，在妇科癌症亚型中死亡率最高。大多数卵巢癌在晚期才被诊断出来，导致五年生存率约为30%。卵巢癌的早期诊断已将五年生存率提高到≥90%，因此当前的迫切需求是识别能够实现疾病早期检测、诊断和进展监测的生物标志物，或新型治疗靶点。在本研究中，通过质谱法对来自纯化的卵巢对照细胞、良性细胞和癌细胞的分泌蛋白进行了研究，以识别易于在患者血清中定量的新型特异性标志物。与卵巢癌细胞相比，共有9种蛋白质显示出对照细胞和良性细胞分泌的显著差异。随后通过逆转录-定量聚合酶链反应评估了其中3种蛋白质（Dickkopf蛋白3、10 kDa热休克蛋白和凝溶胶蛋白）的mRNA表达水平。结合血清中的蛋白质水平，本研究确定凝溶胶蛋白可能是卵巢癌的一个有用标志物。
